Skip to content

Danish National Randomized Study on Early Aortic Valve Replacement in Patients With Asymptomatic Severe Aortic Stenosis

Danish National Randomized Study on Early Aortic Valve Replacement in Patients With Asymptomatic Severe Aortic Stenosis

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03972644
Acronym
DANAVR
Enrollment
1700
Registered
2019-06-03
Start date
2020-01-01
Completion date
2029-09-01
Last updated
2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Valve Stenosis, Diastolic Dysfunction

Brief summary

The purpose of this study is to examine the impact of early surgery in patients with asymptomatic severe aortic valve stenosis with signs of subclinical LV dysfunction despite preserved LVEF, with a watchfull waiting approach.

Detailed description

Since the seminal paper by Ross and Braunwald, the development of symptoms has been regarded as one of the most important precursors of a poor outcome in aortic stenosis (AS), and is today half a century later, still the leading reason for referral for aortic valve replacement (AVR). The development of symptoms is however often preceded by structural changes in the left ventricle (LV).These changes including concentric remodeling and LV hypertrophy have been regarded as compensative measures to adapt the LV to increased ventricular afterload. Although LV hypertrophy may preserve wall-stress in the normal range and increase contractility allowing the preservation of stroke volume, this occurs at the expense of increased filling pressures. Diastolic dysfunction with increased filling pressure lead to left atrial (LA) dilatation and significantly contributes to the development of symptoms. Despite successful surgery, AS patients have increased long-term mortality and morbidity compared to the general population, and the outcome is largely determined by the degree of preoperative structural LV and LA alterations. This has led to the theory that AVR prior to the development of symptoms could improve outcome, a view supported by prospective and retrospective studies.These studies were however small, with some important limitations. In addition, there has been a concern that operative risk and prosthetic valve related long-term morbidity and mortality does not justify surgery on every asymptomatic patient with severe AS. Numerous studies have suggested that markers of LV structure and function, particularly LA volume index,E/e' and brain natriuretic peptides (BNP) all reflecting LV filling pressures may identify patients with benefit of early AVR. Accordingly, the most recent European guideline for management of valvular disease has implemented BNP as a class IIa recommendation for AVR in asymptomatic AS patients,although no randomized studies have demonstrated that early surgery based on these markers improve prognosis. The purpose of this study is thus to evaluate if early AVR in patients with signs of elevated LV filling pressuresmay improve long-term outcome in patients with asymptomatic severe AS, compared to conventional symptom-guided surgery.

Interventions

PROCEDUREAortic valve replacement

Open heart surgery or transcatheter surgery

Sponsors

Rigshospitalet, Denmark
CollaboratorOTHER
Aarhus University Hospital
CollaboratorOTHER
Aalborg University Hospital
CollaboratorOTHER
Zealand University Hospital
CollaboratorOTHER
Odense University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* 1\. Severe AS defined as 1. aortic valve area (AVA) ≤1 cm2, AND 2. Transvalvular maximum velocity (Vmax) ≥3.5 m/s AND 3. AS severity evaluated severe by a heart valve team conference. In cases where severity is not unambiguous an integrative approach will be utilized combining echocardiographic markers of valve severity and LV function, and if necessary aortic valve calcification estimated by non-contrast CT. 2\. Considered to be asymptomatic (estimated by a consultant in cardiology) 3. Considered to be candidate for AVR (transcatheter AVR/surgical AVR) 4. Sign of increased LV filling pressures18 or reduced longitudinal LV systolic function <!-- --> 1. Left atrial volume index (LAVi) \> 34 ml/m2; OR 2. ratio of early diastolic peak mitral inflow velocity (E) to early mitral annulus diastolic velocity (e') ratio E/e'avg\>13; OR 3. Threefold elevation in NT-proBNP compared to the upper expected age and gender value. OR 4. GLS\>-15 5. Age ≥18 years 6. Signed informed consent

Exclusion criteria

1. LVEF\<50% 2. Very severe AS defined as Vmax\>5 m/s. 3. Concomitant severe valvular disease other than AS 4. Previous valvular surgery 5. Estimated glomerular filtration rate\<30 ml/min/m2 6. Dementia 7. Women of childbearing potential 8. Inability to provide informed consent 9. Age\>85 years. 10. Supravalvular or subvalvular AS

Design outcomes

Primary

MeasureTime frameDescription
all-cause mortalityAfter 379 events (approx 5 years)All-cause mortality assessed by Danish patient records

Secondary

MeasureTime frameDescription
Combined endpointAfter 379 events (approx 5 years)All-cause mortality + hospitalization due to heart failure and stroke
all-cause mortality in patients with low-gradient ASAfter 379 events (approx 5 years)All-cause mortality in patients with meangradient \<40 mmHg
Combined endpoint in low-gradient ASAfter 379 events (approx 5 years)All-cause mortality + hospitalization to heart failure and stroke when MG\<40 mmHg

Other

MeasureTime frameDescription
Pericardiocentesis5 yearsNeed of pericariocentesis
major bleeding5 yearsintracerebral bleeding or bleeding resulting in substantial hemodynamic compromise requiring treatment instability
sternal infection5 yearshospitalization due to sternal infection
Persistent renal failure5 yearscomplete loss of renal function exceeding 4 weeks.
endocarditis5-yearshospitalization due to endocarditis

Countries

Denmark

Contacts

Primary ContactJordi S Dahl, MD, PhD
jordi.dahl@rsyd.dk+4523823016
Backup ContactJacob E Møller, MD, PhD
jem@dadlnet.dk

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026